Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more
Boule Diagnostics AB (publ) (BDABF) - Net Assets
Latest net assets as of September 2024: $254.90 Million USD
Based on the latest financial reports, Boule Diagnostics AB (publ) (BDABF) has net assets worth $254.90 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($538.50 Million) and total liabilities ($283.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $254.90 Million |
| % of Total Assets | 47.34% |
| Annual Growth Rate | 12.1% |
| 5-Year Change | 42.73% |
| 10-Year Change | N/A |
| Growth Volatility | 18.62 |
Boule Diagnostics AB (publ) - Net Assets Trend (2014–2023)
This chart illustrates how Boule Diagnostics AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Boule Diagnostics AB (publ) (2014–2023)
The table below shows the annual net assets of Boule Diagnostics AB (publ) from 2014 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $475.10 Million | +2.72% |
| 2022-12-31 | $462.50 Million | +56.39% |
| 2021-12-31 | $295.74 Million | +9.81% |
| 2020-12-31 | $269.30 Million | -19.10% |
| 2019-12-31 | $332.87 Million | +10.64% |
| 2018-12-31 | $300.86 Million | +14.93% |
| 2017-12-31 | $261.77 Million | +13.93% |
| 2016-12-31 | $229.76 Million | +21.88% |
| 2015-12-31 | $188.51 Million | +10.90% |
| 2014-12-31 | $169.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Boule Diagnostics AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12598900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $98.53 Million | 20.74% |
| Other Components | $376.56 Million | 79.26% |
| Total Equity | $475.10 Million | 100.00% |
Boule Diagnostics AB (publ) Competitors by Market Cap
The table below lists competitors of Boule Diagnostics AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Text S.A.
PINK:LCHTF
|
$223.95 Million |
|
Beneteau SA
LSE:0K8N
|
$224.03 Million |
|
Sveafastigheter
ST:SVEAF
|
$224.05 Million |
|
PropertyGuru Group Ltd
NYSE:PGRU
|
$224.06 Million |
|
HAYPP GROUP AB
F:8QG0
|
$223.91 Million |
|
KSL Holdings Bhd
KLSE:5038
|
$223.89 Million |
|
Logistea AB Series B
ST:LOGI-B
|
$223.85 Million |
|
Jiangsu Safety Wire Rope
SHG:603028
|
$223.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Boule Diagnostics AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 462,504,000 to 475,096,000, a change of 12,592,000 (2.7%).
- Net income of 24,977,000 contributed positively to equity growth.
- New share issuances of 149,507,000 increased equity.
- Other factors decreased equity by 161,892,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $24.98 Million | +5.26% |
| Share Issuances | $149.51 Million | +31.47% |
| Other Changes | $-161.89 Million | -34.08% |
| Total Change | $- | 2.72% |
Book Value vs Market Value Analysis
This analysis compares Boule Diagnostics AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $13.48 | $7.84 | x |
| 2018-12-31 | $15.49 | $7.84 | x |
| 2019-12-31 | $17.14 | $7.84 | x |
| 2020-12-31 | $13.87 | $7.84 | x |
| 2021-12-31 | $10.79 | $7.84 | x |
| 2022-12-31 | $11.91 | $7.84 | x |
| 2023-12-31 | $12.23 | $7.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Boule Diagnostics AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.26%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.37%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 1.59x
- Recent ROE (5.26%) is below the historical average (7.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 17.80% | 9.87% | 1.10x | 1.65x | $13.27 Million |
| 2015 | 8.14% | 4.63% | 1.05x | 1.67x | $-3.50 Million |
| 2016 | 15.68% | 8.99% | 1.10x | 1.59x | $13.06 Million |
| 2017 | 14.23% | 8.70% | 1.03x | 1.59x | $11.06 Million |
| 2018 | 13.64% | 9.67% | 0.85x | 1.66x | $10.95 Million |
| 2019 | 11.28% | 7.53% | 0.85x | 1.76x | $4.26 Million |
| 2020 | -17.81% | -11.98% | 0.83x | 1.78x | $-74.90 Million |
| 2021 | 7.87% | 5.02% | 0.81x | 1.93x | $-6.30 Million |
| 2022 | 2.75% | 2.32% | 0.72x | 1.64x | $-33.52 Million |
| 2023 | 5.26% | 4.37% | 0.76x | 1.59x | $-22.53 Million |
Industry Comparison
This section compares Boule Diagnostics AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $498,972,584
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Boule Diagnostics AB (publ) (BDABF) | $254.90 Million | 17.80% | 1.11x | $223.94 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-2.23 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $187.53 Billion |
| Acarix AB (publ) (ACIXF) | $51.88 Million | -150.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $3.82 Million |
| Adm Tronics Unltd (ADMT) | $644.00K | 0.00% | 0.66x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $732.88K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $916.00 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $8.41 Million |